- Home
- ARQT vs OCS Comparison
ARQT vs OCS Comparison
Compare ARQT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- OCS
- Stock Information
- Founded
- ARQT 2016
- OCS 2003
- Country
- ARQT United States
- OCS Switzerland
- Employees
- ARQT N/A
- OCS N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- OCS Health Care
- Exchange
- ARQT Nasdaq
- OCS Nasdaq
- Market Cap
- ARQT 1.1B
- OCS 953.8M
- IPO Year
- ARQT 2020
- OCS N/A
- Fundamental
- Price
- ARQT $13.08
- OCS $22.64
- Analyst Decision
- ARQT Strong Buy
- OCS Strong Buy
- Analyst Count
- ARQT 5
- OCS 5
- Target Price
- ARQT $17.00
- OCS $28.80
- AVG Volume (30 Days)
- ARQT 2.0M
- OCS 104.7K
- Earning Date
- ARQT 02-25-2025
- OCS 03-17-2025
- Dividend Yield
- ARQT N/A
- OCS N/A
- EPS Growth
- ARQT N/A
- OCS N/A
- EPS
- ARQT N/A
- OCS N/A
- Revenue
- ARQT $138,708,000.00
- OCS $1,027,571.00
- Revenue This Year
- ARQT $209.03
- OCS $6.21
- Revenue Next Year
- ARQT $49.00
- OCS $760.04
- P/E Ratio
- ARQT N/A
- OCS N/A
- Revenue Growth
- ARQT 182.84
- OCS N/A
- 52 Week Low
- ARQT $3.59
- OCS $10.55
- 52 Week High
- ARQT $16.20
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- ARQT 46.24
- OCS 85.17
- Support Level
- ARQT $12.61
- OCS $21.80
- Resistance Level
- ARQT $14.36
- OCS $23.08
- Average True Range (ATR)
- ARQT 0.98
- OCS 0.57
- MACD
- ARQT -0.32
- OCS 0.43
- Stochastic Oscillator
- ARQT 13.09
- OCS 92.90
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.